Macromolecular Drugs: Novel Strategy In Target Specific Drug Delivery 1020-1023
DR. SHARMA R, 216-A, Last Morh, Gandhi Nagar , Jammu-J&K- India.e.mail: email@example.com
Macromolecular drugs are polymer-conjugated drugs, polymeric micelles, liposomal drugs or solid phase depot formulations of various agents. Macromolecular drugs can target selectively, solid tumours by exploiting abnormalities of tumour vasculature, namely, hypervascularisation; aberrant vascular architecture; extensive production of vascular permeability factors stimulating extravasation within tumour tissues; and lack of lymphatic drainage. Dextrans are polysaccharide macromolecular carriers devoid of selective transport properties and may serve as one of the most promising carrier candidates for a wide variety of therapeutic agents like hormones (oxytocin and vasopressin), iron, methotraxate, etc. Bone targeting by conjugation of drugs with bisphosphates has shown promise in enhancing their effects in bones and reducing adverse drug reactions. Tetracyclinâ€“conjugated estradiol and oligopeptideâ€“conjugated estradiol are the other novel boneâ€“specific drug carriers (oligopeptides) with high affinity for hydroxyapatite crystals.